Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875011 | 0.89 | POLB (0.35) | TP53GRM2POLBLMNAPKM | |
| SCHEMBL4873926 | 0.86 | MMP1 (0.38) | TP53POLBLMNAPKMMMP3 | |
| SCHEMBL4868934 | 0.85 | MEN1 (0.31) | MEN1NPC1KMT2A | |
| SCHEMBL4870427 | 0.85 | TP53 (0.35) | TP53GRM2POLBLMNAPKM | |
| SCHEMBL4873615 | 0.85 | LMNA (0.34) | TP53POLBLMNAPKMMEN1 | |
| SCHEMBL4875529 | 0.83 | TP53 (0.37) | TP53GRM2POLBLMNAPKM | |
| SCHEMBL4874248 | 0.82 | LMNA (0.41) | POLBLMNAPKMSLC6A9 | |
| SCHEMBL4875410 | 0.79 | MEN1 (0.41) | TP53LMNAMEN1NPC1KMT2A | |
| SCHEMBL4875568 | 0.79 | MEN1 (0.41) | TP53LMNAMEN1NPC1KMT2A | |
| SCHEMBL4870323 | 0.77 | CYP2D6 (0.35) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | TP53 2501/4885GRM2 198/4885POLB 4496/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | TP53 2540/4885GRM2 168/4885POLB 4520/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | TP53 2540/4885GRM2 168/4885POLB 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.